Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy. On January 14, Rodman & Renshaw initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $48 price target, citing the company’s differentiated hematology-focused pipeline and progress across multiple clinical-stage assets. The firm views Ascentage’s approach to addressing drug resistance in blood cancers as a key driver of upside as its next-generation programs advance toward clinica ...